Skip to main content
Fig. 5 | BMC Public Health

Fig. 5

From: Halo and spillover effect illustrations for selected beneficial medical devices and drugs

Fig. 5

Annual and cumulative patient exposure to Tysabri (2004-2012). Data are from Elan Corporation or Biogen Idec Inc. Fourth Quarter Reports for each calendar year and are based on information from the TYSABRI Outreach: Unified Commitment to Health (TOUCH) prescribing program database and other third party sources. Arrows identify key dates of FDA initial approval (November 23, 2004), withdrawal (February 28, 2005), re-market authorization under the TOUCH restricted distribution program (June 5, 2006), FDA approval of Tysabri for Crohn’s Disease (January 14, 2008), and approval of a new test to assist in PML risk stratification for Tysabri

Back to article page
\